CN102940702B - Medicine composition for treating cardia-cerebrovascular diseases - Google Patents
Medicine composition for treating cardia-cerebrovascular diseases Download PDFInfo
- Publication number
- CN102940702B CN102940702B CN201210428513.3A CN201210428513A CN102940702B CN 102940702 B CN102940702 B CN 102940702B CN 201210428513 A CN201210428513 A CN 201210428513A CN 102940702 B CN102940702 B CN 102940702B
- Authority
- CN
- China
- Prior art keywords
- water
- radix paeoniae
- paeoniae rubra
- folium crataegi
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a medicine composition for treating cardia-cerebrovascular diseases, comprising red peony root, Chinese hawthorn leaf, and Ligusticum wallichii. The medicine composition disclosed herein can clear heat and cool blood, activate blood circulation and promote qi circulation, disperse blood stasis and dredge collateral, and has good curative effect on congestive cerebrovascular disease.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, relating in particular to a kind of is the medicament that raw material is made by Radix Paeoniae Rubra, Folium Crataegi and Rhizoma Chuanxiong.
Background technology
People's health in the cardiovascular and cerebrovascular disease serious threats such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, learn according to Epidemiological study, the M & M of cardiovascular and cerebrovascular disease is all in rising trend in recent years, in worldwide, the sickness rate of cardiovascular and cerebrovascular disease is 140-200/10 ten thousand people, its average mortality is 1,00/,100,000 people, has leapt to first of various diseases at the mortality rate of China's cardiovascular and cerebrovascular disease.In the pathogenic factor of cardiovascular and cerebrovascular disease, atherosclerosis is main cause, and it is the pathogenesis basis of hypertension, coronary heart disease, myocardial infarction, apoplexy cardiovascular and cerebrovascular disease.Suppressing blood coagulation, improve blood fluidity, is one of key areas of cardiovascular medicament research and development.
In the medicine of cardiovascular and cerebrovascular disease, Chinese medicine and western medicine is all applied, and Chinese medicine is little and occupy the larger market share with its toxic and side effects, but its curative effect not rapidly, effective ingredient is not obvious, medication dose is large.
Summary of the invention
Object of the present invention is just to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can be regulated the flow of vital energy, effect of promoting blood circulation to remove obstruction in the collateral.
The technical solution adopted for the present invention to solve the technical problems is:
Treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is to be the medicament that raw material is made by Radix Paeoniae Rubra, Folium Crataegi and Rhizoma Chuanxiong.
The weight proportion of pharmaceutical composition of the present invention medicine material used can be: Radix Paeoniae Rubra 8-20 part, Folium Crataegi 3-12 part, Rhizoma Chuanxiong 1-6 part.
The optimum ratio of pharmaceutical composition of the present invention medicine material used is: Radix Paeoniae Rubra 10-18 part, Folium Crataegi 6-10 part, Rhizoma Chuanxiong 2-4 part.
The raw materials used best proportioning of pharmaceutical composition of the present invention is: 15 parts of Radix Paeoniae Rubra, 8 parts of Folium Crataegi, 3 parts of Rhizoma Chuanxiongs.
The dosage form of pharmaceutical composition of the present invention can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, granule.
Pharmaceutical composition of the present invention can be applicable to the treatment of the cardiovascular and cerebrovascular disease such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract.
(2) get Folium Crataegi medical material by formula proportion, add the water of 8-10 times of volume, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with the 50-95% alcohol reflux of 8-10 times of volume 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15-1:20), first washes with water, and this water elution liquid is discarded, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(4) said extracted thing is mixed, make acceptable various pharmaceutical dosage form.
In pharmaceutical composition of the present invention, Radix Paeoniae Rubra hardship, taste is micro-cool, returns Liver Channel.Clearing away heat and cooling blood, can promoting blood circulation to remove obstruction in the collateral.Shennong's Herbal: " Radix Paeoniae, bitter in the mouth is flat.Main pathogen stomachache, except arthralgia due to stagnation of blood ... " long-term pharmacological evaluation shows that Radix Paeoniae Rubra can significantly reduce the plasma total cholesterol levels of hyperlipemia rabbit, significantly improves immunomodulating, Immunosuppression inflammation.
Folium Crataegi nature and flavor acid, flat, returns lung meridian, have antipruritic, sore, blood pressure lowering.Cure mainly dermatitis rhus, ulcer being unable to heal, hypertension.Modern pharmacological research shows that Folium Crataegi can resist acute myocardial ischemia, dwindles its myocardial infarct size; Can show very much the anticoagulant that lands.In addition, can also blood fat reducing, have and make whole blood contrast viscosity show the effect declining.
Rhizoma Chuanxiong acrid in the mouth is warm in nature, returns Liver Channel, gallbladder meridian, pericardium channel, has the function of blood circulation promoting and blood stasis dispelling, activating QI to alleviate the depression, wind-expelling pain-stopping.Cure mainly: menoxenia; Amenorrhea dysmenorrhea; The stagnant raw meat pain of the stasis of blood in puerperal; Mass in the abdomen lump; Pain in chest and hypochondrium; Have a headache dizzy; Anemofrigid-damp arthralgia; Traumatic injury; Ulcer sores.Modern pharmacological research shows, Rhizoma Chuanxiong can increase coronary flow, improves myocardial ischemia situation, extends the platelet aggregation time of ADP induction in vitro, and the platelet of having assembled is had to depolymerisation.
Compared with prior art, the invention has the beneficial effects as follows: this pharmaceutical composition is by being that medicine material is made by Radix Paeoniae Rubra, Folium Crataegi and Rhizoma Chuanxiong, can activating blood circulation to dissipate blood stasis, again can promoting the circulation of blood dissipating depression of QI, blood-activating analgetic, QI and blood is ruled together, and curative effect is significantly improved.Prove that through pharmacodynamics test it is evident in efficacy.
The specific embodiment
Below in conjunction with the specific embodiment, the present invention is described in further detail.
Embodiment 1
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Radix Paeoniae Rubra 15g, Folium Crataegi 8g, Rhizoma Chuanxiong 3g.
Above-mentioned medicinal raw material is prepared into soft capsule, and preparation method is as follows:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect ethanol elution, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract.
(2) get Folium Crataegi medical material by formula proportion, add the water of 10 times of volumes, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 95% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15), first washes with water, and this water elution liquid is discarded, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(4) by said mixture and vegetable oil 25g, mix, make capsule casing material with gelatin, be pressed into soft capsule.
Embodiment 2
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Radix Paeoniae Rubra 20g, Folium Crataegi 10g, Rhizoma Chuanxiong 6g.
Above-mentioned medicinal raw material is prepared into injectable powder, and preparation method is as follows:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect ethanol elution, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract.
(2) get Folium Crataegi medical material by formula proportion, add the water of 10 times of volumes, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 50% alcohol reflux of 10 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:20), first washes with water, and this water elution liquid is discarded, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(4) said mixture is dissolved in 1000mL water for injection, filters, adopt existing preparation of injection, make injectable powder.
Embodiment 3
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated, is made up of the medicinal raw material of following weight: Radix Paeoniae Rubra 8g, Folium Crataegi 3g, Rhizoma Chuanxiong 1g.
Above-mentioned medicinal raw material is prepared into soft capsule, and preparation method is as follows:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract.
(2) get Folium Crataegi medical material by formula proportion, add the water of 8 times of volumes, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 70% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15), first washes with water, and this water elution liquid is discarded, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(4) by said mixture and vegetable oil 25g, mix, make capsule casing material with gelatin, be pressed into soft capsule.
Test example
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test one: the pharmacodynamics test that rat " rabbit brain powder-macromolecule glucosan " is caused to the therapeutical effect of cerebral infarction
Principle: because cardiovascular and cerebrovascular disease all can cause hemorheological change, so can design medicine rat " rabbit brain powder-macromolecule glucosan " is caused the pharmacodynamics test of the therapeutical effect of cerebral infarction, investigate the change of hemorheological property after cerebral infarction to measure whole blood viscosity under different shear rates, investigate erythrocyte deformability with erythrocyte albumen ringer solution viscosity, thereby investigate the therapeutical effect of medicine to cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female half and half.Equipment: cone and plate viscometer, centrifuge, scale centrifuge tube, eye scissors, ophthalmic tweezers and conventional operating theater instruments, 0 trumpeter's art silk thread, vascular clamp etc.
Medicine and reagent:
15 parts of test example 1:(Radix Paeoniae Rubra, 8 parts of Folium Crataegi, 3 parts of Rhizoma Chuanxiongs);
20 parts of test example 2:(Radix Paeoniae Rubra, 10 parts of Folium Crataegi, 6 parts of Rhizoma Chuanxiongs);
8 parts of test example 3:(Radix Paeoniae Rubra, 3 parts of Folium Crataegi, 1 part of Rhizoma Chuanxiong);
15 parts of comparative example 1:(Radix Paeoniae Rubra, 8 parts of Folium Crataegi);
15 parts of comparative example 2:(Radix Paeoniae Rubra, 3 parts of Rhizoma Chuanxiongs).
Above medicine adopts following method to be prepared into test sample:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract.
(2) get Folium Crataegi medical material by formula proportion, add the water of 8 times of volumes, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 70% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15), first washes with water, and this water elution liquid is discarded, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(4) said extracted thing is mixed, obtain corresponding test sample.
With the positive medicine contrast of commercially available Breviscapini injection; Rabbit brain powder (rabbit brain powder thromboplastin powder).Get the rabbit brain powder between sub-sieve 120-150 order, granule is 100-120 μ m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: 25mg rabbit brain powder is mixed in 10% macromolecule dextran solution 100mL, is placed in 37 ℃ of water-baths 40 minutes.Then, be put in-18 ℃ of refrigerators for subsequent use.Rapid Medical ZT glue.BSA, ringer solution.Heparin sodium: add test tube by 20u/mL blood dosage, 40 ℃ of following dry for standby.
Test method: 1, prepared by rat cerebral infarction model: rat etherization, lie on the back fixing, skin cropping sterilization, cervical region cuts, and on the left of separating, neck always beats one's brains, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.Press from both sides again a vascular clamp at distal end place.After suppository is shaken up, lunge common carotid artery by 0.03mL/100g rat dosage with 0.25mL syringe, open distal end vascular clamp, suppository is injected.Then, folder closes common carotid artery distal end, extracts syringe needle, with the bonding pin hole of medical adhesive.After 1 minute, decontrol successively the vascular clamp of common carotid artery distal end, proximal part, external carotid artery, recover blood flow, cleaning wound, skin suture.
Medicine on cerebral infarction after the hemorheology impact of different time: rat is divided into administration group (test example 1-3 group or reference examples 1-3 group+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), every group of 12 rats.Administration group, normal saline group all impose operation technique as stated above, and sham operated rats operation technique is identical, but not injected plug agent, with physiologic saline for substitute suppository, is injected in internal carotid artery.
Administration group is in first 3 days oral drugs (test example, reference examples) 1.42g/Kg of operation.Positive drug is in first 1 hour intraperitoneal injection of drugs 1.0mg/Kg of operation.Normal saline group is injected commensurability normal saline.Sham operated rats is not injected any medicine.Every morning administration later 1 time, for three days on end.
Within the 3rd day after surgery, by rat anesthesia (25% urethane 0.3mL/100g body weight, lumbar injection), right common carotid artery blood-letting, in heparin test tube, was measured the whole blood viscosity under different shear rates with cone and plate viscometer in 2 hours.Again that whole blood is centrifugal with 1500rpm, suck upper plasma.Then use 0.25% bovine serum albumin-ringer solution rinsing erythrocyte three times, centrifugal 10 minutes of each 1500rpm.Finally, be in vitro mixed with erythrocyte at scale: albumen was appointed the erythrocyte albumen ringer solution of liquid=6:4, at 20 seconds
-1under shear rate, measure its viscosity.Using erythrocyte albumen ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 ℃ of constant temperature, and experimental result is carried out to statistical test.Concrete numerical value and the results are shown in Table one.
Table one: on the whole blood viscosity impact (unit: mPa.s) of different time after rat cerebral infarction
Note: * * P < 0.05***P < 0.01 all with the comparison of normal saline group.
From table one result of the test, while blocking 3 days, normal saline group is compared with sham operated rats, whole blood viscosity rising (P<0.05), animal model modeling success is described, each administration group all can reduce whole blood viscosity to some extent, and wherein, with the application's effect of drugs best (P<0.01), control drug effect is taken second place.With normal saline group ratio, whole blood viscosity declines, and statistical procedures has significant.
Test two: on senile rat in the thrombotic impact of body
Principle: use unidirectional current continued stimulus common carotid artery 7 minutes, cause tunica intima damage, activate platelet and blood coagulation system, vascular endothelial cell injury, makes PGI simultaneously
2synthetic and discharge and reduce, cause and in carotid artery vascular, form gradually mixed thrombus.When carotid artery vascular endogenous cause of ill thrombosis and when plug flow, blood vessel far-end temperature bust.By temperature sensor monitors blood vessel surface variations in temperature, by instrument automatic alarm, record starts to temperature bust required time from stimulating, and claims duration of congestion OT, i.e. thrombus formation time.Time is shorter, represents more easily to form thrombosis; Otherwise the time is longer, represent more difficult formation thrombosis.
Senile rat can self-assembling formation blood stasis body constitution, easily forms thrombus in vivo.Young rat is difficult for forming thrombosis.Therefore test in the positive contrast of senile rat, with the negative contrast of young rat.
Material: male rat.Young group Mus 3-4 in the age month, body weight 250g left and right.Old group Mus 24-27 in the age month, body weight 500g left and right.Equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.Medicine and reagent: the application's medicine and control drug are with test one, and dosage is 1.42g/Kg; 20mg/mL pentobarbital sodium solution; Normal saline.
Method: experimental group is only given old group rat oral gavage 2mL/ every day, positive controls senile rat and negative control group young rat gavage distilled water 2mL/, continuous 14 days.Drug withdrawal fasting on the same day.Lumbar injection 20mg/mL pentobarbital sodium 0.2mL/100g next day (body weight).Cut skin of neck, separate right carotid artery, transfer stimulating electrode at carotid artery near-end, far-end is transferred the temperature gauge head that connects instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes with damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis forms gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end declines gradually.In the time that blood flow is blocked completely, temperature bust, instrument is reported to the police, and shows duration of congestion OT, and the OT time is shorter, more easily forms thrombosis; The OT time is longer, more difficult formation thrombosis.
Experimental result is carried out to statistical test.Concrete numerical value and the results are shown in Table two.
Table two: on senile rat in the thrombotic impact of body
From table two result of the test, senile rat OT is obviously short compared with young rat, illustrates and easily forms thrombosis.Administration group all can significant prolongation OT, and the application's effect of drugs is (P<0.01) better.
Above result shows, the application's medicine is effective compared with control drug.
Claims (3)
1. a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, is characterized in that, it is to be the medicament that raw material is made by Radix Paeoniae Rubra, Folium Crataegi and Rhizoma Chuanxiong; The weight portion proportioning of medicine material used is: Radix Paeoniae Rubra 8-20 part, Folium Crataegi 3-12 part, Rhizoma Chuanxiong 1-6 part;
Described pharmaceutical composition adopts following methods to extract preparation:
(1) get Radix Paeoniae Rubra medical material by formula proportion, water percolation, collects percolate, and percolate, by macroporous adsorbent resin, is first washed with water, removes the impurity that is dissolved in polar solvent, and this water elution liquid is discarded; Use again 80% high concentration ethanol eluting, collect this high concentration ethanol eluent, the eluent reclaiming after ethanol is dried, obtain Radix Paeoniae Rubra extract;
(2) get Folium Crataegi medical material by formula proportion, add the water of 8-10 times of volume, 80-90 ℃ is extracted 1 time, and extracting solution activated carbon decolorizing is concentrated, dry, obtains Folium Crataegi extract;
(3) get Ligusticum chuanxiong Hort by formula proportion, with the 50-95% alcohol reflux of 8-10 times of volume 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, obtain extractum, be dissolved in water, sucking filtration, filtrate is crossed macroporous resin column, and the volume ratio of extractum and resin is 1:15-1:20, first washes with water, this water elution liquid is discarded, then uses 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract;
(4) said extracted thing is mixed, make acceptable various pharmaceutical dosage form.
2. treatment cardiovascular and cerebrovascular disease according to claim 1 pharmaceutical composition of the present invention, is characterized in that the weight portion proportioning of medicine material used is: Radix Paeoniae Rubra 10-18 part, Folium Crataegi 6-10 part, Rhizoma Chuanxiong 2-4 part.
3. treatment cardiovascular and cerebrovascular disease according to claim 2 pharmaceutical composition of the present invention, is characterized in that the weight portion proportioning of medicine material used is: 15 parts of Radix Paeoniae Rubra, 8 parts of Folium Crataegi, 3 parts of Rhizoma Chuanxiongs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428513.3A CN102940702B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428513.3A CN102940702B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940702A CN102940702A (en) | 2013-02-27 |
| CN102940702B true CN102940702B (en) | 2014-05-28 |
Family
ID=47723762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210428513.3A Active CN102940702B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940702B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515276A (en) * | 2003-01-08 | 2004-07-28 | 北京国际生物制品研究所 | Medicine for preventing restenosis after interventional therapy of coronary heart disease and/or curing coronary heart disease and its preparation method |
| CN1679698A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method |
| CN101036708A (en) * | 2006-03-14 | 2007-09-19 | 广东奇方药业有限公司 | Medicine composition for treatment of cardio-cerebralvascular disease |
| CN102258588A (en) * | 2011-03-10 | 2011-11-30 | 张建军 | Preparation method of peony general glycoside |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100440863B1 (en) * | 2001-05-24 | 2004-07-19 | 한국원자력연구소 | Extract of herb mixture for heamatopoiesis augmentation and protection from radiation |
| CN1272036C (en) * | 2002-12-18 | 2006-08-30 | 江苏康缘药业股份有限公司 | Medicinal injection for treating cardio-cerebrovascular disease and preparing method thereof |
| CN100496543C (en) * | 2005-09-27 | 2009-06-10 | 鲁南制药集团股份有限公司 | Injection for treating cardiac cerebrovascular disease and its preparation |
| CN1857442A (en) * | 2006-03-17 | 2006-11-08 | 崔彬 | Preparation and application of ligustrazine and its salt composition |
| WO2010110755A1 (en) * | 2009-03-27 | 2010-09-30 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
| CN102068520B (en) * | 2010-12-30 | 2012-07-25 | 广州博济医药生物技术股份有限公司 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
-
2012
- 2012-10-31 CN CN201210428513.3A patent/CN102940702B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515276A (en) * | 2003-01-08 | 2004-07-28 | 北京国际生物制品研究所 | Medicine for preventing restenosis after interventional therapy of coronary heart disease and/or curing coronary heart disease and its preparation method |
| CN1679698A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method |
| CN101036708A (en) * | 2006-03-14 | 2007-09-19 | 广东奇方药业有限公司 | Medicine composition for treatment of cardio-cerebralvascular disease |
| CN102258588A (en) * | 2011-03-10 | 2011-11-30 | 张建军 | Preparation method of peony general glycoside |
Non-Patent Citations (1)
| Title |
|---|
| 曾建国.山楂.《植物提取物标准化研究-方法与示范》.化学工业出版社,2011,(第1版),第110页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940702A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100447148C (en) | Cape jasmine extract , its preparing process and application | |
| CN102028700B (en) | Medicinal composition and preparation method thereof | |
| CN101244234B (en) | Medicaments for preventing and controlling ischemia and hemorrhagic cerebrovaseular disease, and preparation thereof | |
| CN100546615C (en) | Be used for the treatment of Chinese medicine composition of cerebrovascular and preparation method thereof | |
| CN101987112B (en) | Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102940668B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN103520193A (en) | Pharmaceutical composition and preparation method thereof | |
| CN102940675B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940702B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940658A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940676B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940694B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940680B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104367630A (en) | American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104367656A (en) | Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN100415241C (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
| CN104435213A (en) | Persimmon-leaf-containing traditional Chinese medicine composition for treating cardia-cerebrovascular disease | |
| CN105380985B (en) | Pharmaceutical composition for treating cerebral arterial thrombosis | |
| CN104840613A (en) | Medicine composition for treating primary alveolar hydatid disease as well as preparation method and application thereof | |
| CN100381125C (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN104398550A (en) | Ginkgo biloba containing Chinese medicinal composition for treatment of cardia-cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG YUEYUE INDUSTRY CO., LTD. Free format text: FORMER OWNER: CHENGDU YILUKANG MEDICAL TECHNOLOGY SERVICE CO., LTD. Effective date: 20150317 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 226131 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150317 Address after: 226131 Jiangsu city of Nantong Province Haimen Yuelai town Fuxing Road, building 12, the town government compound Patentee after: Nantong Yue Yue Industrial Co., Ltd. Address before: Science Park high tech Zone of Chengdu South Road, No. 88 610041 Sichuan province Tianfu Life Science Park building B6 No. 9 Patentee before: Chengdu Yilukang Medical Technology & Service Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220419 Address after: 017000 No. 069, Albas sumuhu and tolgaigacha, otok banner, Ordos City, Inner Mongolia Autonomous Region Patentee after: Anan Yutaka Address before: 226131 Government Courtyard, Building 12, Fuxing Road, Yuelai Town, Haimen City, Nantong City, Jiangsu Province Patentee before: NANTONG LEYUE INDUSTRIAL LTD. |